These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24012486)

  • 1. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging.
    Seynhaeve ALB; Dicheva BM; Hoving S; Koning GA; Ten Hagen TLM
    J Control Release; 2013 Nov; 172(1):330-340. PubMed ID: 24012486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
    Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
    J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.
    Ito K; Hamamichi S; Asano M; Hori Y; Matsui J; Iwata M; Funahashi Y; Umeda IO; Fujii H
    Cancer Sci; 2016 Jan; 107(1):60-7. PubMed ID: 26509883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular PK/PD Relationships of Free and Liposomal Doxorubicin: Quantitative Analyses and PK/PD Modeling.
    Soininen SK; Vellonen KS; Heikkinen AT; Auriola S; Ranta VP; Urtti A; Ruponen M
    Mol Pharm; 2016 Apr; 13(4):1358-65. PubMed ID: 26950248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors.
    Laginha KM; Verwoert S; Charrois GJ; Allen TM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6944-9. PubMed ID: 16203786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular trafficking of a pH-responsive drug metal complex.
    Kheirolomoom A; Ingham ES; Commisso J; Abushaban N; Ferrara KW
    J Control Release; 2016 Dec; 243():232-242. PubMed ID: 27746275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice.
    Wang H; Zheng M; Gao J; Wang J; Zhang Q; Fawcett JP; He Y; Gu J
    Talanta; 2020 Feb; 208():120358. PubMed ID: 31816795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model.
    Smith JA; Mathew L; Burney M; Nyshadham P; Coleman RL
    Gynecol Oncol; 2016 May; 141(2):357-363. PubMed ID: 26946092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.
    Zhao Y; Alakhova DY; Kim JO; Bronich TK; Kabanov AV
    J Control Release; 2013 May; 168(1):61-9. PubMed ID: 23474033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin.
    Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Kikuchi H; Ishihara H
    Int J Pharm; 2014 Dec; 476(1-2):205-12. PubMed ID: 25280884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin.
    Song H; Zhang J; Han Z; Zhang X; Li Z; Zhang L; Fu M; Lin C; Ma J
    Cancer Chemother Pharmacol; 2006 May; 57(5):591-8. PubMed ID: 16133530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative evaluation of liposomal doxorubicin and its metabolites in spheroids.
    Lukowski JK; Hummon AB
    Anal Bioanal Chem; 2019 Nov; 411(27):7087-7094. PubMed ID: 31471684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations.
    Luo R; Li Y; He M; Zhang H; Yuan H; Johnson M; Palmisano M; Zhou S; Sun D
    Int J Pharm; 2017 Mar; 519(1-2):1-10. PubMed ID: 28063903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel two-step mild hyperthermia for advanced liposomal chemotherapy.
    Li L; ten Hagen TL; Haeri A; Soullié T; Scholten C; Seynhaeve AL; Eggermont AM; Koning GA
    J Control Release; 2014 Jan; 174():202-8. PubMed ID: 24269966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quantitative study of the intracellular fate of pH-responsive doxorubicin-polypeptide nanoparticles.
    Wang J; Bhattacharyya J; Mastria E; Chilkoti A
    J Control Release; 2017 Aug; 260():100-110. PubMed ID: 28576641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance guided high-intensity focused ultrasound mediated hyperthermia improves the intratumoral distribution of temperature-sensitive liposomal doxorubicin.
    de Smet M; Hijnen NM; Langereis S; Elevelt A; Heijman E; Dubois L; Lambin P; Grüll H
    Invest Radiol; 2013 Jun; 48(6):395-405. PubMed ID: 23399809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manganese-52: applications in cell radiolabelling and liposomal nanomedicine PET imaging using oxine (8-hydroxyquinoline) as an ionophore.
    Gawne P; Man F; Fonslet J; Radia R; Bordoloi J; Cleveland M; Jimenez-Royo P; Gabizon A; Blower PJ; Long N; de Rosales RTM
    Dalton Trans; 2018 Jul; 47(28):9283-9293. PubMed ID: 29796500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.